Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Cancers

Cancers

Recruiting

Comparing treatments for newly diagnosed multiple myeloma patients

The purpose of this study is to compare the standard of care therapy (VRd + Rd therapy) and CAR-T therapy (VRd + CAR-T) for newly diagnosed multiple myeloma patients who do not plan to receive hematopoietic stem cell transplant as initial therapy.

Status
Recruiting
Principal Investigator
Kevin Song
Body Locations and Systems
Blood, Heart and Circulation
Age
18 and above

Optimizing drug treatment for chronic myelogenous leukemia

The purpose of this study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), who have previously been treated with at least 2 tyrosine kinase inhibitors. Additionally, this study will investigate the usage of two different dosing regimes of asciminib, 80mg daily and 40mg twice daily.

Status
Recruiting
Principal Investigator
Donna Forrest
Body Locations and Systems
Blood, Heart and Circulation
Age
18 and above

Genetic testing to prevent and treat male breast cancer

The purpose of this study is to identify inheritable mutations among male breast cancer participants by performing genetic testing on their cancer samples, instead of blood samples (such as tumour testing). This testing will allow researchers to identify inheritable mutations when blood samples are not available. This study will evaluate the clinical utility and the feasibility of offering the tumour testing in newly diagnosed male breast cancer patients.

Status
Recruiting
Age
19 and above

A web-based peer navigation program for men with prostate cancer

The purpose of this study is to evaluate the effect of a peer navigation program for men with prostate and a peer navigator training course called the True North Peer Navigation program. The study will evaluate patient outcomes such as their ability to take a more active role in their health, quality of life, social support and use of health care services, in addition to the experiences of patients and peer navigators and the factors that make it easier or harder for people to deliver the program to patients in different settings.

Status
Recruiting
Principal Investigator
Arminee Kazanjian

Assessing Shoulder and Arm Issue Related to Treatment for Breast Cancer

The purpose of this study is to understand how to assess for shoulder and arm problems women may experience related to breast cancer and its treatment and to help women know when it may be appropriate to seek physiotherapy care.

Status
Recruiting
Principal Investigator
Kristin Campbell
Area
Vancouver
Age
19 and above

APIxaban Cancer Associated Thrombosis (API-CAT)

The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of CC-97540 CAR-T cell treatment for subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.

Status
Recruiting
Principal Investigator
Kevin Hay
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL

The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.

Status
Recruiting
Principal Investigator
Yasser Abou Mourad
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Aerobic Exercise and Cognitive Functioning in Women with Breast Cancer (ACTIVATE)

The purpose of this study is to evaluate the impact of an aerobic exercise intervention on Chemotherapy-Related Cognitive Changes (CRCC) in women diagnosed with breast cancer who undergo chemotherapy.

Status
Recruiting
Principal Investigator
Kristin Campbell
Area
Vancouver
Age
19 - 70

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

The purpose of the study is to test the safety and efficacy of a drug known as CC-220 in combination with other treatments for multiple myeloma patients. 

Status
Recruiting
Principal Investigator
Kevin Song
Area
Vancouver
Age
18 and above

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.

Status
Recruiting
Principal Investigator
David Sanford
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC

The purpose of this study is to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.

Status
Recruiting
Principal Investigator
Bernhard Eigl
Area
Vancouver
Age
18 and above

Predicting the Quality of Response to Specific Treatments (PQRST)

This study is an longitudinal observation study to enroll patients who have chronic graft versus host host disease and  are about to receive initial or second line treatment, in order to identify predictors of treatment response. 

Status
Recruiting
Principal Investigator
Jennifer White
Area
Vancouver
Age
18 and above

PC 360 Survivorship

Prostate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to these needs through survivorship care. The current randomized control trail (RCT) will focus on the development and evaluation of a facilitated electronic Prostate Cancer Survivorship Care Plan (PC-SCP).

Status
Recruiting
Principal Investigator
Larry Goldenberg
Body Locations and Systems
Prostate Cancer
Area
Vancouver
Age
18 and above

International Lung Screen Trial (ILST)

People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.

Status
Recruiting
Principal Investigator
Stephen Lam
Body Locations and Systems
Lung Cancer
Area
Vancouver
Age
55-80

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2)

This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome.

Status
Recruiting
Principal Investigator
Janice Kwon
Body Locations and Systems
Ovarian Disorders
Area
Vancouver
Age
18-70

A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma (ADAM)

This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a prospective, cohort study of 24 participants with multiple myeloma, in whom a lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible participants will initiate thromboprophylaxis with apixaban prior to starting their DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and plasma drug concentration will be measured.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood
Area
Vancouver
Age
19 and above

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients. In 20% of patients however, the disease is either initially unresponsive to IM (Imatinib), resistance develops within a few months, or blast crisis occurs early and unexpectedly following an initial response.

Status
Recruiting
Principal Investigator
Donna Forrest
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)

Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased quality of life. Prevention is the most effective way to decrease the complications associated with blood clots in the veins.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood Clots
Area
Vancouver
Age
18 and above

Closed for Recruitment

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. After progressive disease (PD), patients in the Vd Arm may cross over to SVd treatment. Patients who cross over will be referred to as SVdX patients.

Status
Closed for Recruitment
Principal Investigator
Heather J. Sutherland
Body Locations and Systems
Blood
Area
Vancouver
Age
18 years and above

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page
Subscribe to Cancers

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy